Amino Acid, Peptide, or Protein
Pfizer’s Sasanlimab Shows 32% Reduction in Bladder Cancer Risk But Misses Secondary Endpoints in Phase 3 CREST Trial
Sasanlimab (PD-1 inhibitor), Bladder cancer risk reduction, Phase 3 CREST trial, BCG combination therapy, Non-muscle invasive bladder cancer (NMIBC), Event-free survival (EFS), Overall survival (OS) endpoint missed, Subcutaneous administration
Keytruda around head and neck cancer surgery cuts chance of disease coming back
Keytruda, Head, perioperative, Episodic
Compounding pharmacies dealt a blow in fight over end of semaglutide shortage
United States Food and Drug Administration, semaglutide, Compound, enforcement, Pharmacy facility, shortage, Wegovy
Halozyme sues Merck over subcutaneous Keytruda as licensing talks fall through
Merck, Legal patent, Subcutaneous Keytruda, Halozyme
Ex-FDA leader joins new initiative designed to fight ‘unfortunate reality’ of vaccine landscape
Vaccines, Project, Misinformation, Initiative, Policy, Intact, Ex-FDA, threat, Recommendation, M.D., reality
Versant’s Granite Bio unveils with $100M for new autoimmune disease antibodies
Autoimmune Diseases, granite, GRT-001, Versant, interleukin-3
Novavax’s COVID-19 jab looks to be on track for approval
Vaccines, COVID19 (disease), United States Food and Drug Administration, Approved, Novavax, Novavax ‘s, Novavax
Akeso, Summit’s PD-1/VEGF bispecific records another pivotal study win in NSCLC
Ivonescimab, Non-Small Cell Lung Carcinoma, Akeso, PD-1/VEGF, Keytruda, summit, Pharmacotherapy, Combined, Safety
German cancer antibody biotech eyes SPAC as route to Nasdaq
Veraxa, Antibodies, SPAC, German language, Nasdaq
Facing added pressure from Eli Lilly, Novo Nordisk submits for FDA approval of oral GLP-1 obesity drug
Nordisk, Obesity, Approved, Oral cavity, Glucagon-Like Peptide 1, Market, Pressure- physical agent, eli lilly, competition, Novo, semaglutide, United States Food and Drug Administration, United States Food and Drug Administration